High tariffs on generic drugs threaten most US medicines and hit Indian pharma
A steep tariff on generic drugs would materially disrupt supply and pricing for pharmaceuticals, especially Indian-supplied medicines.
Source →The trace
How it reaches your house.
Starting from Antidepressants and mental health medications, we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Sun Pharmaceutical Industries →Shortage riskA tariff hit to Sun would materially tighten buprenorphine API supply because this edge shows Sun holding a 56% market share.
89% confidencePsychiatric Drug Active Pharmaceutical Ingredients →Prices riseIndia accounts for 55% of this input in the graph, and the tariff policy is specifically aimed at Indian generic exporters, making the Indian sourcing channel the most exposed.
87% confidencePsychiatric Drug Active Pharmaceutical Ingredients →Prices riseAntidepressants and mental health medications
This input is a critical 98%-dependent upstream for antidepressants and mental-health medicines, so tariff pressure on generic/API supply would pass through as higher costs for the downstream drugs.
Hop 2
India →Prices risePalvella Therapeutics, Inc.PVLA
Palvella says its rapamycin API is sourced from suppliers in India, so a tariff on Indian generic-drug inputs would directly raise its input costs and could tighten supply.
91% confidenceCorticosteroid APIs (betamethasone, clobetasol, triamcinolone) →Shortage riskTopical and dermatology Rx products
These corticosteroid APIs are a critical, high-dependency input for topical and dermatology prescription products, so tariff-driven API disruption would materially constrain finished-product supply.
91% confidenceTacrolimus API (FK506) →Prices easeHop 3
Divi's Laboratories Limited →Prices riseFluoroquinolone APIs (ciprofloxacin HCl, ofloxacin, moxifloxacin HCl)
Divi's 12% share and 18-month replacement window for fluoroquinolone APIs make tariff pressure likely to lift landed costs and limit near-term substitution.
73% confidenceDr. Reddy's Laboratories →Shortage riskCamptothecin (botanical extract)
If tariffs constrain Dr. Reddy's output, camptothecin supply from this supplier tightens; the 10% share, low substitutability, and 18-month replacement time amplify the shortage.
70% confidenceTopical and dermatology Rx products →Prices riseCorticosteroid APIs (betamethasone, clobetasol, triamcinolone)
Where it lands
What you buy, and what you own.
Goods you buy
Antidepressants and mental health medications · Topical and dermatology Rx products
Companies you may own
SUNPHARMA.NSAUROPHARMA.NSPVLA543952.BO4503.TRDYIPCALABDivi's Laboratories LimitedBIOCON.NSDr. Reddy's Laboratories
Tap a company to see what it told the SEC could break it.
In the MyPRIA app, this is checked against your own holdings.